GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (LTS:0JQ2) » Definitions » ROE % Adjusted to Book Value

Kala Bio (LTS:0JQ2) ROE % Adjusted to Book Value : -197.87% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Kala Bio ROE % Adjusted to Book Value?

Kala Bio's ROE % for the quarter that ended in Mar. 2024 was -666.83%. Kala Bio's PB Ratio for the quarter that ended in Mar. 2024 was 3.37. Kala Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -197.87%.


Kala Bio ROE % Adjusted to Book Value Historical Data

The historical data trend for Kala Bio's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kala Bio ROE % Adjusted to Book Value Chart

Kala Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only -23.01 -39.73 -52.07 -240.92 -124.03

Kala Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -189.24 -97.33 -114.38 -143.40 -197.87

Competitive Comparison of Kala Bio's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Kala Bio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kala Bio's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kala Bio's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Kala Bio's ROE % Adjusted to Book Value falls into.



Kala Bio ROE % Adjusted to Book Value Calculation

Kala Bio's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-318.75% / 2.57
=-124.03%

Kala Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-666.83% / 3.37
=-197.87%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kala Bio ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Kala Bio's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Kala Bio (LTS:0JQ2) Business Description

Industry
Traded in Other Exchanges
Address
1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Kala Bio (LTS:0JQ2) Headlines

No Headlines